Critical Outcome Technologies Inc receives orphan drug designation for COTI-2

Tuesday, 17 Jun 2014 09:00am EDT 

Critical Outcome Technologies Inc:U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer.With its p53 dependent mechanism of action, COTI-2 is a novel compound with the potential to benefit these patients, as more than 95 pct of serious ovarian cancers have a p53 gene mutation. 

Company Quote

0.0050 +1.85%
23 Jul 2014